ArticleFrontiers in microbiology2021
Continual Decline in Azole Susceptibility Rates in
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 38 citations in OpenAlex.
- Population genomics reveals a long-term increase in azole resistance associated with the emerging cluster AZR amongEmerging microbes & infections · 2026Article
- Integrated Genomic and Phenotypic Analyses Reveal Convergent Resistance Patterns in Clinical Candida tropicalis Isolates.Mycoses · 2026Article
- Epidemiology, antifungal susceptibility, risk factors, and mortality of adult candidemia at a tertiary hospital in Eastern China from 2020 to 2025.BMC infectious diseases · 2026Article
- A quiet but growing threat: Global perspectives on antifungal resistance and future therapeutic approaches.Indian journal of pharmacology · 2026Review
- Antifungal Drug Susceptibility Profiles and Molecular Mechanisms of Azole Resistance ofInfection and drug resistance · 2026Article
- Article
- Rapid antifungal phenotypic detection ofFrontiers in cellular and infection microbiology · 2026Article
- Genomic Insights into Azole Resistance Mechanisms in Candida tropicalis Among Hematological Malignancy Patients with Candidemia.Current microbiology · 2025Article
- Antifungal and Immunomodulatory Activities of Brazilian SavannahPharmaceuticals (Basel, Switzerland) · 2025Article
- Understanding the mechanisms of resistance to azole antifungals inJAC-antimicrobial resistance · 2025Review
- Synergistic antifungal activity of minocycline as an effective augmenting agent of fluconazole against drug-resistantMicrobiology spectrum · 2025Article
- Adaptive morphological changes link to poor clinical outcomes by conferring echinocandin tolerance in Candida tropicalis.PLoS pathogens · 2025Article
- An agricultural triazole induces genomic instability and haploid cell formation in the human fungal pathogen Candida tropicalis.PLoS biology · 2025Article
- Research progress on the drug resistance mechanisms ofFrontiers in microbiology · 2025Review
- Article
- Prevalence, Mortality, Antifungal Resistance, and Risk Factors of Candidemia Among Cancer Patients in a Single Center of Southern China: A 10-Year Retrospective Study.Journal of tropical medicine · 2025Article
- Epidemiology risk factors and antifungal resistance patterns ofFrontiers in microbiology · 2025Article
- [Clinical features and prognosis of children with fungal bloodstream infection following chemotherapy for acute leukemia].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Article
- Antifungal Susceptibility Data and Epidemiological Distribution ofAntibiotics (Basel, Switzerland) · 2024Article
- Geraniol Potentiates the Effect of Fluconazole against Planktonic and Sessile Cells of Azole-ResistantPharmaceutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThere have been reports of increasing azole resistance in
methodsFrom August 2009 to July 2018,
resultsOverall, 22.2% (823/3702) of the isolates were resistant to fluconazole, with 90.4% (744/823) being cross-resistant to voriconazole. In addition, 16.9 (370/2192) and 71.7% (1572/2192) of the isolates were of non-wild-type phenotype to itraconazole and posaconazole, respectively. Over the 9 years of surveillance, the fluconazole resistance rate continued to increase, rising from 5.7 (7/122) to 31.8% (236/741), while that for voriconazole was almost the same, rising from 5.7 (7/122) to 29.1% (216/741), with no significant statistical differences across the geographic regions. However, significant difference in fluconazole resistance rate was noted between isolates cultured from blood (27.2%, 489/1799) and those from non-blood (17.6%, 334/1903) specimens (
conclusionThe continual decrease in the rate of azole susceptibility among
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.